Osmotic Diuretics

Osmotic Diuretics: MOA - The Water Pullers

• Pharmacologically inert, low molecular weight (LMW) substances.
• Freely filtered at the glomerulus.
• Undergo minimal or no tubular reabsorption.
• Primary sites of action (water-permeable segments):
  • Proximal Convoluted Tubule (PCT)
  • Descending Limb of Loop of Henle (DLH)
• Core Mechanism: "The Water Pullers"
  • Increase osmolality of tubular fluid.
  • Create an osmotic gradient, holding water in the lumen.
  • ↓ Water reabsorption → ↑ Urine volume (osmotic diuresis).

⭐ Osmotic diuretics cause a greater excretion of water than of Na+ and other electrolytes, leading to "aquaresis" (water diuresis).

Osmotic Agents: Key Drugs - Meet the Osmotics

📌 MUGI: Mannitol, Urea, Glycerin, Isosorbide.

• Mannitol (Prototype)
  • Route: IV infusion.
  • PK: Unmetabolized, freely filtered, minimal tubular reabsorption.
  • Onset: 30-60 min (diuresis); Peak ICP ↓: 1-2 hrs. Duration: 6-8 hrs.
  • ⭐ > Test dose (0.2 g/kg IV over 3-5 min) advised in marked oliguria or suspected inadequate renal function to check for adequate urine flow (target >30-50 mL/hr).
• Urea
  • Route: IV (less common now due to side effects).
  • PK: Filtered, ~40-50% reabsorbed. Smaller molecule than mannitol.
  • Caution: Phlebitis, tissue irritation/necrosis if extravasated.
• Glycerin (Glycerol)
  • Route: Oral.
  • PK: Metabolized (provides calories, ~4.32 kcal/g).
  • Use: Acute glaucoma. Caution: Hyperglycemia. Onset: 10-30 min.
• Isosorbide
  • Route: Oral.
  • PK: Dihydric alcohol (chemically distinct from isosorbide dinitrate/mononitrate).
  • Use: Short-term reduction of Intraocular Pressure (IOP); glaucoma. Well tolerated orally.

Osmotic Diuretics: Uses - When to Call the Pullers

• Cerebral Edema & ↑ Intracranial Pressure (ICP):
  • Rapidly reduces ICP in head injury, brain tumors.
  • Decreases brain bulk during neurosurgery.
• Acute Glaucoma & ↑ Intraocular Pressure (IOP):
  • Emergency management of acute angle-closure glaucoma.
  • Pre/post-operatively for ocular surgeries to lower IOP.
• Acute Renal Failure (ARF) Prophylaxis:
  • Maintains urine flow, prevents tubular obstruction (e.g., rhabdomyolysis, hemolysis).
  • During major surgeries (cardiovascular, trauma) with risk of renal hypoperfusion.

  ⭐ Mannitol is the primary osmotic diuretic used for rapid, short-term reduction of acutely raised intracranial pressure.

• Forced Diuresis:
  • Accelerates renal elimination of certain toxins/drug overdoses (e.g., salicylates, barbiturates).
• Dialysis Disequilibrium Syndrome:
  • Prevents cerebral edema by minimizing osmotic shifts during initial hemodialysis sessions.

Osmotic Diuretics: Risks - Handle With Care

• ⚠️ Adverse Effects (AEs):
  • Initial & transient: Extracellular fluid (ECF) volume ↑
    • Risk: Pulmonary edema (esp. in Heart Failure - HF), worsening cardiac status.
  • Prolonged use: Dehydration, electrolyte imbalances (hypernatremia, hypokalemia - monitor closely!).
  • Common: Headache, nausea, vomiting.
  • Mannitol-specific: Acute Kidney Injury (AKI) with high doses/renal impairment; hypersensitivity (rare).
• ⚠️ Contraindications (CIs):
  • Anuria (severe renal failure, unresponsive to test dose).
  • Active intracranial bleeding (except during craniotomy).
  • Severe pulmonary congestion or frank pulmonary edema.
  • Severe dehydration.
  • Established/decompensated Heart Failure.
  • Progressive renal damage or oliguria after mannitol therapy.

⭐ Mannitol's initial ECF volume expansion can acutely worsen heart failure or pulmonary edema before diuresis is established.

High‑Yield Points - ⚡ Biggest Takeaways

• Mannitol (IV) is the prototype; acts by ↑ osmotic pressure in PCT & Loop of Henle.
• Reduces intracranial pressure (cerebral edema) and intraocular pressure (acute glaucoma).
• Used for prophylaxis of acute renal failure by maintaining urine flow.
• Initial ECF expansion can worsen heart failure or cause pulmonary edema.
• Later effects include dehydration, hypernatremia, and hyperkalemia.
• Contraindicated in anuria, severe dehydration, and active intracranial bleeding.